To provide a medical device including a substrate and a hydrophilic polymer layer formed on at least a part of the substrate, which satisfies the following conditions (a) to (d): (a) a polymer constituting the hydrophilic polymer layer is a hydrophilic polymer having an acidic group; (b) the hydrophilic polymer layer has a thickness of 1 nm or more and less than 100 nm; (c) a number ratio of basic group/acidic group of the hydrophilic polymer layer is 0.2 or less; and (d) a liquid film retention time at 40 minutes after ultrasonic cleaning in a phosphate buffer solution is 15 seconds or more. The present invention provides a medical device in which a surface of a substrate is hydrophilized, and a method for manufacturing same by a simple method.

Absorbable barrier composites are designed for modulated gas and water permeability depending on clinical use and are formed of at least two physicochemically distinct components, one of which is a film adjoined to a knitted mesh and/or electrostatically spun, non-woven fabric. Depending on the physicochemical properties of the barrier composite, it can be used in neurological and urinogenital surgical procedures as well as tissue engineering and/or as physical barriers to prevent adhesion formation following several types of surgical procedures.

The present patent application is directed to compositions and shaped structures implantable into mammalian bodies, the compositions and shaped structures having localized bioactive surfaces.

A threaded medical implant comprising a biocomposite, said biocomposite comprising a polymer and a plurality of reinforcement fibers, wherein a weight percentage of a mineral composition within the biocomposite medical implant is in the range of 30-60%, wherein an average diameter of said fibers is in a range of 1-100 microns, said medical implant being threaded with a plurality of threads; wherein said fibers comprise a plurality of helical fibers and a plurality of longitudinal fibers; wherein a weight to weight percent ratio of said helical to said longitudinal fibers is from 90:10 to 10:90.

A pharmaceutical composition is described. The pharmaceutical composition includes a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent. Implantable medical devices coated with the pharmaceutical composition, methods of coating an implantable medical device with the pharmaceutical composition, and methods of treating vascular disease using the pharmaceutical composition are also described.

A conductive human interface includes an insulating body of elastomeric material and a compliant electrode embedded in the insulating body. The electrode is formed from an electrically conductive gel including a polymeric material and conductive particles dispersed in the polymeric material. The conductive particles can be included in the gel in an amount that is not more than about 10% by weight.

There is provided a composition for a laminated material used for a medical lubricating member, the composition including a polymer b1 including a polysiloxane structure and a crosslinkable polymer b2 having a particular reactive group that forms a crosslinked body with the polymer b1 and having a number-average molecular weight of 1000 or more. The crosslinkable polymer b2 is at least one of polysaccharides, polyethyleneimines, polyesters, polyethers, polyamides, polyurethanes, polyureas, or polyimides. There are also provided a laminated material used for a medical lubricating member and including the composition, a medical lubricating member, and a medical device.

Medical devices that are formed from a polymeric matrix including a first polymer and a functionalized polymer are provided. The medical devices may include a functionalized polymer such as maleic anhydride functionalized polymer. The burst strength and/or the hoop strength of the medical devices including the functionalized polymer may be greater than the burst strength and/or the hoop strength of control medical devices. However, the durometer of the medical devices may be substantially equal to the durometer of the control medical devices. Methods of manufacturing medical devices including a functionalized polymer are also provided.

Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.

Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.